Evaluation of Alivecor 6L device and QTc interval software in psychiatric settings

A simple 6-lead ECG device, paired with cloud-based software, is being tested as a faster, less intrusive alternative to the standard 12-lead ECG for monitoring heart safety in psychiatric patients starting antipsychotic medication. This matters because the standard 12-lead ECG requires patients to remove clothing to place electrodes on the chest, which can be a significant barrier for people with mental health conditions who may be distressed, agitated, or uncomfortable with physical exposure. The QTc interval—a measure of the heart’s electrical activity—must be checked before and during antipsychotic treatment to prevent dangerous arrhythmias, but if the ECG itself is difficult to obtain, this safety step can be missed. If the 6-lead Alivecor device and its QTc software prove accurate enough, psychiatric wards and community teams could switch to a simpler, less invasive monitoring method. Patients would not need to undress, and staff could obtain the reading more quickly and with less distress. This could improve compliance with safety monitoring, reduce the risk of undetected heart problems, and make antipsychotic prescribing safer in routine psychiatric care. The research is a direct practical evaluation, not fundamental science—its success would change a specific clinical workflow.